Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression
暂无分享,去创建一个
Ville Mustonen | Johannes Cairns | Tommi Mononen | Otto I. Pulkkinen | Mikhail Shubin | Ignacio Vázquez-García | Jani V Anttila | Florian Borse | Qingli Guo | Otto Pulkkinen | Ville Mustonen | Qingli Guo | Johannes Cairns | T. Mononen | M. Shubin | Florian Borse | I. Vázquez-García | Jani V. Anttila | Mikhail Shubin
[1] Krishnendu Chatterjee,et al. Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.
[2] Wei Liu,et al. Bottom-up precise synthesis of stable platinum dimers on graphene , 2017, Nature Communications.
[3] Martin A. Nowak,et al. Dynamics of chronic myeloid leukaemia , 2005, Nature.
[4] M. Stratton,et al. Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.
[5] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[6] Minsu Kim,et al. Antibiotic-induced population fluctuations and stochastic clearance of bacteria , 2018, eLife.
[7] T. Fojo,et al. Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? , 2007, Clinical Cancer Research.
[8] M. Clynes,et al. Examining the relationship between cancer invasion/metastasis and drug resistance. , 2002, Current cancer drug targets.
[9] Valentina Rossetti,et al. Emergent multicellular life cycles in filamentous bacteria owing to density-dependent population dynamics , 2011, Journal of The Royal Society Interface.
[10] Marc J. Williams,et al. Identification of neutral tumor evolution across cancer types , 2016, Nature Genetics.
[11] Vincent J Schmithorst,et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.
[12] E. E. Gresch. Genetic Alterations During Colorectal-Tumor Development , 1989 .
[13] H. Ohtsuki,et al. Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.
[14] B. Perthame,et al. Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors , 2014, Bulletin of Mathematical Biology.
[15] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[16] Lewis H. Mervin,et al. Understanding Cytotoxicity and Cytostaticity in a High-Throughput Screening Collection. , 2016, ACS chemical biology.
[17] Martin A. Nowak,et al. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity , 2015, Nature.
[18] Sang Gyun Kim,et al. Rapamycin: one drug, many effects. , 2014, Cell metabolism.
[19] R. Busa-Fekete,et al. Antagonism between Bacteriostatic and Bactericidal Antibiotics Is Prevalent , 2014, Antimicrobial Agents and Chemotherapy.
[20] Robert J Woods,et al. How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient , 2017, PLoS biology.
[21] Heyrim Cho,et al. Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy , 2017, Bulletin of Mathematical Biology.
[22] Ahmad S. Khalil,et al. Antibiotic efficacy is linked to bacterial cellular respiration. , 2015, Proceedings of the National Academy of Sciences of the United States of America.
[23] Ville Mustonen,et al. The value of monitoring to control evolving populations , 2014, Proceedings of the National Academy of Sciences.
[24] C. Thompson,et al. The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment , 2007, Clinical Cancer Research.
[25] P. Armitage,et al. The age distribution of cancer and a multi-stage theory of carcinogenesis , 1954, British Journal of Cancer.
[26] M. Tubiana. Tumor cell proliferation kinetics and tumor growth rate. , 1989, Acta oncologica.
[27] Franziska Michor,et al. Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies , 2009, PLoS Comput. Biol..
[28] Sridhar Ramaswamy,et al. Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.
[29] Andrea Sottoriva,et al. Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine , 2016, Trends in cancer.
[30] Robert Gatenby,et al. Opinion: Control vs. eradication: Applying infectious disease treatment strategies to cancer , 2015, Proceedings of the National Academy of Sciences.
[31] Charles Swanton,et al. Metastasis as an evolutionary process , 2016, Science.
[32] Joel s. Brown,et al. Classifying the evolutionary and ecological features of neoplasms , 2017, Nature Reviews Cancer.
[33] William H. Sanders,et al. Dynamic partitioning for hybrid simulation of the bistable HIV-1 transactivation network , 2006, Bioinform..
[34] P. Tchounwou,et al. Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.
[35] Benjamin J. Raphael,et al. The evolutionary history of 2,658 cancers , 2017, Nature.
[36] R. Matkowski,et al. Circulating Tumor , 2014 .
[37] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[38] B. Krishnamachary,et al. Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents , 2016, Front. Oncol..
[39] Martin A. Nowak,et al. Quantifying Clonal and Subclonal Passenger Mutations in Cancer Evolution , 2016, PLoS Comput. Biol..
[40] B. Frieden,et al. Adaptive therapy. , 2009, Cancer research.
[41] Fredrik Ponten,et al. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology , 2010, Nature Reviews Cancer.
[42] B. Leyland-Jones. Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.
[43] M. Erlacher,et al. How cell death shapes cancer , 2015, Cell Death and Disease.
[44] Martin A. Nowak,et al. Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.
[45] Naveen Garg,et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. , 2017, JCI insight.
[46] Melissa L. Johnson,et al. Emerging targeted therapies for breast cancer. , 2007, Hematology/oncology clinics of North America.
[47] O. Ovaskainen,et al. Stochastic models of population extinction. , 2010, Trends in ecology & evolution.
[48] Dominik Wodarz,et al. Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[49] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[50] Troy Day,et al. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy , 2011, Proceedings of the National Academy of Sciences.
[51] Joel s. Brown,et al. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer , 2017, Nature Communications.